株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

眼病薬市場(ドライアイ、抗緑内障、抗アレルギー、抗炎症、抗感染症、網膜疾患用薬剤):世界の業界分析、規模、シェア、成長、動向および予測

Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018

発行 Transparency Market Research 商品コード 294619
出版日 ページ情報 英文 72 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
眼病薬市場(ドライアイ、抗緑内障、抗アレルギー、抗炎症、抗感染症、網膜疾患用薬剤):世界の業界分析、規模、シェア、成長、動向および予測 Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018
出版日: 2014年01月24日 ページ情報: 英文 72 Pages
概要

世界の眼病薬市場は、緑内障やドライアイ、網膜疾患などの眼病罹患率の上昇によって、急速に拡大しています。ライフスタイルの変化、医療インフラの改良、技術改良、医療支出の増加、高齢化などがこの成長を押し上げています。

当レポートでは、世界の眼病薬市場について調査し、市場規模と将来予測、地域別動向、競合環境などをまとめ、企業プロファイルとともに、概略下記の構成で取り上げております。

第1章 序論

第2章 エグゼクティブサマリー

第3章 眼病薬:業界分析

  • イントロダクション
  • 市場促進因子と機会
    • 眼病罹患率の上昇
    • 世界的高齢化
    • 途上国の医療インフラに対する政府のイニシアティブ
    • ドラッグデリバリー技術における技術改良
    • 生活習慣病の罹患率上昇
  • 市場阻害因子と課題
    • 眼病に対する人々の認識不足
    • 眼病薬のパイプライン枯渇
    • ブロックバスター薬の特許失効
    • 途上国における医療保険の不備

第4章 眼病薬市場動向

  • 併用療法への注力
  • 合併買収が眼病薬市場の拡大に寄与

第5章 ポーターズファイブフォース分析

第6章 世界市場規模と予測

第7章 眼病薬市場:治療薬

  • ドライアイ
  • 網膜疾患
  • 抗アレルギー、抗炎症、抗感染症薬
  • 抗緑内障薬

第8章 眼病薬市場:地域別分析

  • 北米におけるシナリオ
  • 欧州におけるシナリオ
  • アジア太平洋地域におけるシナリオ

第9章 処方薬とOTC薬

第10章 競合環境

第11章 企業プロファイル

  • 参天製薬株式会社
  • Pfizer
  • Novartis
  • Roche
  • Allergan

図表

目次

The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, technological changes, increase in healthcare spending and aging population is also supporting the growth of the ophthalmic drugs market.

Glaucoma is the largest drugs segment in global ophthalmic drugs market. Some of the major drugs for glaucoma treatment are Lumigan, Combigan, Xalatan, Ganfort and Saflutan. Diquas, Hyalein and Restasis are the major drugs for dry eye diseases. The retinal drugs market includes Ozurdex, Macugen, Visudyne and Lucentis. Patanol/Pataday, Tobradex, Vigamox and Bepreve are major ocular anti-inflammatory drugs. The ophthalmic drugs market covers prescription based drugs, OTC drugs and pipeline drugs. This report forecasts future potential of all these drug markets and analyses drivers and opportunities, restraints and challenges, market trends, Porter's forces, competitive landscape and company profiles of key players.

The report categorizes the global ophthalmic drugs market based on major eye disorders, treatment drugs and geography. The treatment drugs market comprises treatment of major eye disorders such as glaucoma, dry eye drugs, retinal diseases and ocular inflammatory diseases. The market is further segmented on the basis of prescription based drugs, OTC drugs and pipeline drugs in different eye disorder areas. In the segment of geographic analysis, the report identifies and analyses market sizes and forecast of North America, Europe, Asia Pacific and Rest of the World (RoW). North America region covers the scenario of the US. Europe region covers the scenario of France, Germany and the UK. Asia Pacific region highlights the scenario of India, China and Japan.

Table of Contents

Chapter 1 Preface 8

  • 1.1 Report Description 8
  • 1.2 Research Methodology 8

Chapter 2 Executive Summary 10

Chapter 3 Ophthalmic Drugs - Industry Analysis 11

  • 3.1 Introduction 11
  • 3.2 Market Drivers and Opportunities 11
    • 3.2.1 Increasing prevalence of eye disorders 12
    • 3.2.2 Global aging population 12
    • 3.2.3 Rising government initiatives towards healthcare infrastructure in developing countries 13
    • 3.2.4 Technological changes in drug delivery techniques 14
    • 3.2.5 Increasing prevalence of lifestyle associated diseases 14
  • 3.3 Restraints and Challenges 15
    • 3.3.1 Lack of awareness among people regarding eye disorders 15
    • 3.3.2 Drying pipeline of ophthalmic drugs 15
    • 3.3.3 Patent expiration of blockbuster ophthalmic drugs 16
    • 3.3.4 Absence of health insurance in developing countries 16

Chapter 4 Ophthalmic Drugs Market Trends 18

  • 4.1 Increased focus on combination therapy 18
  • 4.2 Increasing mergers and acquisitions contribute to the growth of ophthalmic drugs market 18

Chapter 5 Porter's Five Force Analysis 20

  • 5.1 Bargaining power of buyers 20
  • 5.2 Bargaining power of suppliers 21
  • 5.3 Threat of new entrants 21
  • 5.4 Threat from substitutes 21
  • 5.5 Degree of competition 21

Chapter 6 Global Market Size and Forecast 22

Chapter 7 Ophthalmic Drugs Market - Treatment Drugs 25

  • 7.1 Dry eye drugs 25
    • 7.1.1 Existing 25
    • 7.1.2 Pipeline 26
  • 7.2 Retinal drugs 27
    • 7.2.1 Existing 27
    • 7.2.2 Pipeline 28
  • 7.3 Ophthalmic anti-allergy/ inflammatory/ infective drugs 29
    • 7.3.1 Existing 29
    • 7.3.2 Pipeline 30
  • 7.4 Anti-glaucoma drugs 31
    • 7.4.1 Existing 31
    • 7.4.2 Pipeline 32

Chapter 8 Ophthalmic Drugs Market: Regional Analysis 34

  • 8.1 Scenario in North America 34
    • 8.1.1 Scenario in the US 36
  • 8.2 Scenario in Europe 38
    • 8.2.1 Scenario in France 41
    • 8.2.2 Scenario in Germany 42
    • 8.2.3 Scenario in the UK 44
  • 8.3 Scenario in Asia Pacific 46
    • 8.3.1 Scenario in India 49
    • 8.3.2 Scenario in China 50
    • 8.3.3 Scenario in Japan 52

Chapter 9 Prescription vs. Over the Counter Drugs 55

Chapter 10 Competitive Landscape 57

Chapter 11 Company Profiles 62

  • 11.1 Santen Pharmaceutical 62
    • 11.1.1 Overview 62
    • 11.1.2 Products and segments 62
    • 11.1.3 Financial Performance 62
  • 11.2 Pfizer 63
    • 11.2.1 Overview 63
    • 11.2.2 Products & Segments 63
    • 11.2.3 Financial Performance 63
  • 11.3 Novartis 64
    • 11.3.1 Overview 64
    • 11.3.2 Products & Segments 64
    • 11.3.3 Financial Performance 65
  • 11.4 Merck 66
    • 11.4.1 Overview 66
    • 11.4.2 Products & Segments 66
    • 11.4.3 Financial Performance 66
  • 11.5 Roche 68
    • 11.5.1 Overview 68
    • 11.5.2 Products & Segments 68
    • 11.5.3 Financial Performance 68
  • 11.6 Allergan 70
    • 11.6.1 Overview 70
    • 11.6.2 Products & Segments 70
    • 11.6.3 Financial Performance 70

List of Figures

  • FIG. 1 Profiles of aging population in major countries (%, 2000-2050) 13
  • FIG. 2 Global ophthalmic drugs market: Porter's five force analysis 20
  • FIG. 3 Key players market share in the global ophthalmic drugs market in 2012 57
  • FIG. 4 Ophthalmic drugs market strategic developments (2011-2013) 58

List of Tables

  • TABLE 1 Drivers for ophthalmic drugs market: Impact analysis 11
  • TABLE 2 Global data on visual impairment, by region (million, 2002 and 2010) 12
  • TABLE 3 Restraints for ophthalmic drugs market: Impact analysis 15
  • TABLE 4 Out of pocket expenditure of developing and developed countries 17
  • TABLE 5 Major combination therapy drugs worldwide 18
  • TABLE 6 Major merger and acquisitions in the ophthalmic drug market 19
  • TABLE 7 Global Ophthalmic drugs market size, by geography 2008-2012 (USD million) 22
  • TABLE 8 Global Ophthalmic drugs market size, by geography 2013-2018(USD millions) 23
  • TABLE 9 Global Ophthalmic drugs market size, by disease 2008-2012 (USD million) 23
  • TABLE 10 Global Ophthalmic drugs market size, by disease 2013-2018 (USD million) 24
  • TABLE 11 Dry eye drugs market 2010-2012 (USD million) 25
  • TABLE 12 Dry eye drugs market 2013-2018 (USD million) 26
  • TABLE 13 Major dry eye drugs pipeline 26
  • TABLE 14 Retinal drugs market 2010-2012 (USD million) 27
  • TABLE 15 Retinal drugs market 2013-2018 (USD million) 28
  • TABLE 16 Major retinal disease drugs pipeline 28
  • TABLE 17 Anti-allergy/inflammatory drugs market 2010-2012 (USD million) 29
  • TABLE 18 Anti-allergy/inflammatory drugs market 2013-2018 (USD million) 30
  • TABLE 19 Major anti-inflammatory/allergy/anti-infective drugs pipeline 30
  • TABLE 20 Prevalence of glaucoma, by geographic regions (million, 2010-2020) 31
  • TABLE 21 Major anti-glaucoma drugs market 2010-2012 (USD million) 32
  • TABLE 22 Major anti-glaucoma drugs market 2013-2018 (USD million) 32
  • TABLE 23 Anti-glaucoma drugs pipeline 33
  • TABLE 24 North America Ophthalmic drugs market size, by geography 2008-2012 (USD million) 34
  • TABLE 25 North America Ophthalmic drugs market size, by geography 2013-2018 (USD million) 35
  • TABLE 26 North America Ophthalmic drugs market size, by disease 2008-2012 (USD million) 35
  • TABLE 27 North America ophthalmic drugs market, by disease 2013-2018 (USD million) 36
  • TABLE 28 Ophthalmic drugs market, by disease in US 2008-2012(USD million) 37
  • TABLE 29 Ophthalmic drugs market by disease in US 2013-2018 (USD million) 37
  • TABLE 30 European Ophthalmic drugs market size, by geography 2008-2012 (USD million) 38
  • TABLE 31 European Ophthalmic drugs market size, by geography 2013-2018 (USD million) 39
  • TABLE 32 European ophthalmic drugs market by disease 2008-2012 (USD million) 40
  • TABLE 33 European ophthalmic drugs market by disease 2013-2018 (USD million) 40
  • TABLE 34 French ophthalmic drugs market by disease 2008-2012 (USD million) 41
  • TABLE 35 French ophthalmic drugs market, by disease 2013-2018 (USD million) 42
  • TABLE 36 German Ophthalmic drugs market, by disease 2008-2012 (USD million) 43
  • TABLE 37 German ophthalmic drugs market, by disease 2013-2018 (USD million) 43
  • TABLE 38 The UK ophthalmic drugs market, by disease 2008-2012 (USD million) 45
  • TABLE 39 The UK ophthalmic drugs market, by disease 2013-2018 (USD million) 45
  • TABLE 40 Asian Ophthalmic drugs market size, by country 2008-2012 (USD million) 46
  • TABLE 41 Asian Ophthalmic drugs market size, by geography 2013-2018 (USD million) 47
  • TABLE 42 Asian ophthalmic drugs market, by disease 2008-2012 (USD million) 47
  • TABLE 43 Asian ophthalmic drugs market, by disease 2013-2018 (USD million) 48
  • TABLE 44 Indian ophthalmic drugs market, by disease 2008-2012 (USD million) 49
  • TABLE 45 Indian ophthalmic drugs market, by disease 2013-2018 (USD million) 50
  • TABLE 46 Chinese ophthalmic drugs market, by disease 2008-2012 (USD million) 51
  • TABLE 47 Chinese ophthalmic drugs market, by disease 2013-2018 (USD million) 52
  • TABLE 48 Japanese ophthalmic drugs market, by disease 2008-2012 (USD million) 53
  • TABLE 49 Japanese ophthalmic drugs market, by disease 2013-2018 (USD million) 53
  • TABLE 50 Ophthalmic drugs market, by prescription vs. over the counter drugs 2008-2012 (USD million) 55
  • TABLE 51 Ophthalmic drugs market, by prescription vs. over the counter drugs 2013-2018 (USD million) 56
  • TABLE 52 Major product launches in ophthalmic drugs market (2011-2013) 59
  • TABLE 53 R&D initiatives in ophthalmic drugs market (2012-2013) 60
  • TABLE 54 Mergers and acquisitions in ophthalmic drugs market (2011-2013) 61
Back to Top